The effect of flux decay on a 20-nm nanofilter for virus

BioPharm International

Volumn 20, Issue 4, 2007, Pages 58-64

  Tarrach, Klaus ^a   Meyer, Anika ^a   Dathe, Julia Elena ^a   Sun, Hanni ^a  

^a SARTORIUS STEDIM BIOTECH GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; POLYETHERSULFONE; PROTEIN;

ARTICLE; BACTERIOPHAGE; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG PURITY; NANOFILTER; NANOTECHNOLOGY; NONHUMAN; PSEUDOMONAS AERUGINOSA; VALIDATION PROCESS; VIRAL CONTAMINATION;

EID: 34247474827     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. International Conference on Harmonization. Q5A. Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Geneva, Switzerland; 1998.
2. Schmidt S, Mora, J, Dolan S, Kauling, J. An integrated concept for robust and efficient virus clearance and contaminant removal in biotech process. BioProcess Int. 2005 Sept.; 3(9):26-31.
3. Immelmann A, Kellings K, Stamm O, Tarrach K. Validation and quality procedures for virus and prion removal in biopharmaceuticals. BioProcess Int. 2005 Sept;3(9):38-44.
4. Cabatingan, M. Impact of virus stock quality on virus filter validation. BioProcess Int. 2005 July;3(7):39-43.
5. Bailey M. Normal flow virus filtration - Detection and assessment of endpoint in bioprocessing. PDA viral safety conference; 2005 May; Tampa, FL.
6. Bolton G, et al. Normal flow virus filtration - Detection and assessment of endpoint in bioprocessing. Biotechnol. Appl. Biochem. 2005;42:133-142.
7. Brorson K. Virus filter validation and performance. Recovery conference; 2006 April; Litchfield, AZ.
8. Tarrach K. Integrative Strategies for viral clearance. 4th annual biological production forum. 2005 April 7; Edinburgh, Scotland.